[Cervix ripening using drugs before oxytocin labor induction. Clinical study of a new prostaglandin E2 triacetin gel].
In an open randomized clinical study, 50 of 100 gravidae with a low Bishop score (less than or equal to 5) at term were treated with prostaglandin E2 (0.5 mg PGE2 in 2.5 ml Triacetin gel. Prepidil, intracervically) 12 hours before the indicated i.v. oxytocin induction. In 50 patients labor was induced intravenously without any pretreatment. In 46 of 50 pretreated women (92%) there was an increase in the Bishop score of at least three points, and of only two points in the remaining four. In the control group no significant increase in the Bishop score was measurable. Sixteen patients delivered within the first 12 hours after PGE2 gel administration, before oxytocin induction. Three women in the untreated control group also delivered during this pre-observation period. In 14 (64%) of 22 women in whom cervical priming with PGE2 was performed and 26 (57%) of 47 patients in whom it was not the first intravenous oxytocin induction was successful. The frequency of cesarean sections was 10% (n = 5) in the PGE2 gel group and 12% (n = 6) in the oxytocin group. The oxytocin dose needed to induce labor was significantly lower after cervical priming. No severe side effects were observed during and after PGE2 treatment, in either the mothers or the children.
D002584:Cervix Uteri / Q000187:drug effects*; D002986:Clinical Trials as Topic; D015232:Dinoprostone; D005260:Female; D005782:Gels / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D007751:Labor, Induced / Q000379:methods*; D010121:Oxytocin / Q000008:administration & dosage*; D011247:Pregnancy; D011458:Prostaglandins E / Q000627:therapeutic use*; D011459:Prostaglandins E, Synthetic / Q000627:therapeutic use*; D011897:Random Allocation; D014215:Triacetin / Q000008:administration & dosage* / Q000627:therapeutic use*; D014280:Triglycerides / Q000008:administration & dosage* / Q000627:therapeutic use*
D005782:Gels; D011458:Prostaglandins E; D011459:Prostaglandins E, Synthetic; D014280:Triglycerides; D010121:Oxytocin; D015232:Dinoprostone; D014215:Triacetin
Medikamentöse Zervixreifung vor Oxytocin-Geburtseinleitung. Klinische Studie mit einem neuen Prostaglandin E2-Triacetin-Gel.